SCHEDULE: Anson Funds Discloses 4.9% Stake in Silo Pharma

Anson Funds Management LP and affiliated entities have disclosed a 4.9% beneficial ownership stake in Silo Pharma, Inc., primarily through common stock and exercisable warrants.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam (collectively, 'Reporting Persons') have filed an Amendment No. 1 to Schedule 13G.
• The Reporting Persons beneficially own 699,486 shares of Silo Pharma, Inc. common stock.
• This represents 4.9% of the outstanding common stock of Silo Pharma, Inc.
• The ownership includes common stock underlying outstanding warrants, subject to a beneficial ownership limitation of 4.99%.
• The percentage is calculated based on 13,318,273 common shares outstanding as of November 13, 2025, plus the 699,486 shares receivable upon warrant exercise, totaling 14,017,759 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Silo Pharma, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A reputable institutional investor group taking a significant, albeit passive, stake suggests a vote of confidence in Silo Pharma's value proposition without indicating any immediate control-related issues.

Positives

• A significant institutional investor group, Anson Funds, has taken a substantial, albeit passive, stake in Silo Pharma, indicating potential confidence in the company's long-term prospects.
• The investment is explicitly stated to be for ordinary course of business, not for control, suggesting a stable, long-term investment horizon from this group.

Negatives

• The beneficial ownership is capped at 4.9%, just below the 5% threshold that would typically trigger a Schedule 13D filing, which requires more detailed disclosure of investment intent and potential influence. This could be seen as a deliberate strategy to remain passive and avoid more stringent reporting requirements.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
• The foreign regulatory scheme applicable to Anson Advisors Inc. is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s).

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal investor confidence or strategic positioning within an industry. For a company like Silo Pharma, which operates in a specialized sector (likely biotech/pharma given its name and common stock structure), the involvement of a fund like Anson Funds could be viewed positively by the market, suggesting validation of its business model or pipeline.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could instill confidence among existing shareholders and potentially attract new investors, as it signals institutional interest.
• Management: Management might view this as a validation of their strategy, though they should remain aware of the potential for increased scrutiny from a large shareholder, even if passive.

Key Dates

Recommendation

The disclosure of a 4.9% passive stake by Anson Funds is a positive signal, indicating institutional interest and potential long-term value. However, without additional information on Silo Pharma's operational performance, financial health, or strategic initiatives, this filing alone does not warrant a 'buy' recommendation. The investment is explicitly passive, meaning Anson Funds does not intend to influence control, which limits the immediate catalyst for a significant price movement based solely on this ownership. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future developments and the company's performance.

Keywords

Silo Pharma, Anson Funds, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, equity stake, SEC filing